Exploring the Relationships between Targeted Structures and Antitumor Activities of Nuclear-Targeted Polypeptide-Functionalized Platinum(IV) Prodrugs
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c01110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Ruihan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 2501…. Hauptthemen laut MEDLINE: Prodrugs, Antineoplastic Agents, Peptides, Platinum. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Medical and Health Science and Technology Development Project of Shandong Province, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Polypeptides as drug delivery vehicles can achieve the targeted therapeutic effects of first-line platinum drugs in clinical practice, providing an important method to solve problems such as the high systemic toxicity of first-line platinum drugs. In this work, we employ a rational molecular conjugation strategy to design and synthesize two platinum(IV) prodrugs. The first, s-CisPt(IV)-TAT, is linked to a single nuclear-targeting polypeptide, while the second, d-CisPt(IV)-TAT, is conjugated with two of these polypeptides. Interestingly, despite the higher degree of functionalization, disubstituted d-CisPt(IV)-TAT exhibits lower reactivity and cytotoxicity than its monosubstituted counterpart. This counterintuitive result suggests that overloading with multiple ligands may reduce cellular uptake, thereby compromising therapeutic efficacy. Furthermore, both constructs are shown to induce apoptosis via DNA damage pathways, confirming their mechanism of action. These results underscore the importance of precisely tuning the ligand density in drug carriers. Our work provides valuable insights into the structure-activity relationships governing platinum prodrugs and highlights the need for a balance between functional density and biological performance in the design of next-generation polypeptide-conjugated chemotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, Shandong, China.
ORCID-Profile: Chunyu Zhang
Förderung
- Medical and Health Science and Technology Development Project of Shandong Province
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Academic Promotion Program of Shandong First Medical University
Zitieren
APA
Li, R., Yin, X., Chong, C., Li, Y., Yao, Q., Mu, Y., & Zhang, C. (2025). Exploring the Relationships between Targeted Structures and Antitumor Activities of Nuclear-Targeted Polypeptide-Functionalized Platinum(IV) Prodrugs. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01110
Vancouver
Li R, Yin X, Chong C, Li Y, Yao Q, Mu Y, et al. Exploring the Relationships between Targeted Structures and Antitumor Activities of Nuclear-Targeted Polypeptide-Functionalized Platinum(IV) Prodrugs. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c01110
BibTeX
@article{Li2025,
author = {Li, Ruihan and Yin, Xuan and Chong, Chuanke and Li, Yan and Yao, Qingqiang and Mu, Yanling and Zhang, Chunyu},
title = {Exploring the Relationships between Targeted Structures and Antitumor Activities of Nuclear-Targeted Polypeptide-Functionalized Platinum(IV) Prodrugs},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c01110}
}
EUVIMED